Aurobindo Pharma Ltd 2019 AR2
The report highlights Aurobindo Pharma's financial and operational performance for the fiscal year 2018-19, during which it became the 10th largest generic company globally by revenue. Key achievements include the acquisition of Apotex's commercial operations in five European countries and the acquisition of seven branded oncology injectable products from Spectrum Pharmaceuticals. On the sustainability front, the company received SA 8000 accreditation for two of its formulation facilities and expanded its wastewater treatment capacities using Membrane Bio-Reactor technology. Additionally, Aurobindo joined the AMR Industry Alliance to actively combat antimicrobial resistance.
Company: Aurobindo Pharma Ltd
Sector: Manufacturing
Country: India
Year: 2019
Type: AR2
Pages: 296
Back to company
Aurobindo Pharma Ltd
Annual Report
The report highlights Aurobindo Pharma's financial and operational performance for the fiscal year 2018-19, during which it became the 10th largest generic company globally by revenue. Key achievements include the acquisition of Apotex's commercial operations in five European countries and the acquisition of seven branded oncology injectable products from Spectrum Pharmaceuticals. On the sustainability front, the company received SA 8000 accreditation for two of its formulation facilities and expanded its wastewater treatment capacities using Membrane Bio-Reactor technology. Additionally, Aurobindo joined the AMR Industry Alliance to actively combat antimicrobial resistance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees